Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRushir J. ChoksiXWXiaogang WangBCBeverly Chigarira

Discussion

Loading...

Member takes

Overview

Observational analysis revealed significant toxicity leading to discontinuation of acalabrutinib in CLL patients, indicating potential benefits of transitioning to zanubrutinib.

Key Points

  • Most patients had discontinued acalabrutinib within one year due to toxicity and adverse events.
  • The retrospective cohort included 806 CLL patients, with 121 switching to zanubrutinib after acalabrutinib.
  • Median duration of zanubrutinib therapy after acalabrutinib was 10.7 months, with 57.8% remaining on treatment.
  • Phase data supports the continued clinical efficacy of zanubrutinib in patients with a history of prior BTK inhibitors.

Cite This Study

Choksi et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2ffhttps://doi.org/10.1182/blood-2025-8041
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy2025
  2. 2Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  3. 3Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis2025
  4. 4Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting2025 · 2 citations
  5. 5Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL2026